March 12, 202111:00am-1:00pm EasternJoin us to learn about BARDA's interests and how BARDA can help you advance scientific and product development.
BARDA's CBRN Division seeks partners for its Vaccine Portfolio
Submit proposal 
Partnering Pre-IND to late stage Vaccine Development (BARDA) 
FDA vaccine review and licensure 
Vaccines will Save Lives The BARDA Antibacterials program is well known for investments in small molecules since its launch in 2010, including supporting FDA approval of three antibiotics. But BARDA’s investments go beyond antibiotics. The BARDA CBRN Vaccine program has invested in efforts that led to FDA licensure of vaccines against smallpox and Ebola. And through CARB-X, the portfolio has expanded to include non-traditional products and currently supports the development of four vaccines.
Through the existing BAA (BAA-18-100-SOL-00003), BARDA is looking to support programs for vaccines for MDR pathogens in the late preclinical stage through phase II clinical development.
Learn more or apply
BARDA partners with CARB-X for support of preclinical development of vaccines for MDR/DR pathogens. CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
More information about CARB-XBARDA's Pathogens of Interest: These four pathogens are among the top public health threats because of their cost, incidence, morbidity and mortality, and their overlap with other public health emergencies. AMR can hinder emergency response by worsening outcomes, regardless of root cause.
Vaccine Against Drug Resistant Threats Requirements
Note: Updates to BAA pending. Klebsiella pneumoniae will be added and Acinetobacter baumannii will be removed
Join BARDA at the Vaccines against AMR Threats virtual workshop on March 12, 2021 from 11:00am - 1:00pm Eastern.
View Workshop Agenda
About the Event
Help BARDA fight AMR! Join the workshop to learn more about BARDA, our mission, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts, followed by a structured discussion, and Q&A.
All Stakeholders Invited
Companies and others interested in working with BARDA are encouraged to attend the March 12, 2021 workshop. The event is open to the public, but space is limited. Be sure to register by March 5, 2021. Please, no more than four people from one organization.
One-on-One Meetings
Are you a product developer working on a vaccine against one of the four targeted pathogens? Then we want to talk with you! Be sure to request a private meeting when you register for the workshop.
